Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 3 | Porcine Health Management

Fig. 3

From: TbpB-based oral mucosal vaccine provides heterologous protection against Glässer’s disease caused by different serovars of Spanish field isolates of Glaesserella parasuis

Fig. 3

Evaluation of the efficacy of the oral mucosal TbpB-based vaccine in piglets immunized against Glässer’s disease throughout a seven-day experiment. A Survival rate, expressed as percentage, of immunized and non-immunized piglets challenged with four different serovars (SVs) of G. parasuis. B Clinical score average (0–3) and standard deviation of immunized and non-immunized piglets, itemized into six different clinical signs. No non-immunized piglet survived after the third day of challenge. Differences per group were evaluated with the Wilcoxon rank-sum test

Back to article page

Porcine Health Management

ISSN: 2055-5660

Contact us